Finzati - Logo
HALO logo

Halozyme Therapeutics, Inc.

HALO • Biotechnology
$0.00
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$10.17B
Growth
30.2%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 22.7%Positive revenue growth · 38.7%Positive free cash flow · 5.38Consistent free cash flow · 5/5Healthy liquidity · 4.66
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 12:34 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.00
Change0.00%
Market Cap$10.17B
52W Range61.23 - 86.00
Beta0.84
Gross Margin78.13%
Oper. Margin58.45%
Profit Margin22.69%
Debt/Eq43.89
Current Ratio4.66
Quick Ratio3.66
Revenue 5Y30.23%

Investment DNA

How strong this company looks for long-term investors

81
out of 100
Business Quality
Margins, moat, returns
77/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
58/100
Why this score▼
Stable or improving margins · 22.7%Positive revenue growth · 38.7%Positive free cash flow · 5.38Consistent free cash flow · 5/5Healthy liquidity · 4.66High debt level · 43.89

Analyst view

Analyst sentiment and price target

Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-08-07
Low
$75.00
Mean
$93.25
Median
$91.50
High
$115.00

Company Overview

IPO: 3/16/2004
Industry: Biotechnology
P/B i: 165.22
Debt / Equity i: 43.89
Operating Margin: 58.45%
Net Margin: 22.69%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 43.89
Current Ratio: 4.66
Quick Ratio: 3.66
Status: Good

Warnings

  • High debt level

Insider Transactions

Recent executive and insider activity

Torley Helen
Transaction: 07/08/2026
SELL
Change
-1,923
Price
$12.07
Filing
07/09/2026
Type
SELL
Torley Helen
Transaction: 07/08/2026
SELL
Change
-1,035
Price
$80.19
Filing
07/09/2026
Type
SELL
Connaughton Bernadette
Transaction: 07/01/2026
SELL
Change
-625
Price
$77.21
Filing
07/02/2026
Type
SELL